Adolescent Asthma Study

Ages Eligible for Study: Ages 12-21
Sexes Eligible for Study: All


The VECTOR Study is a clinical research study for those with moderate to severe asthma, looking at flu vaccination alongside treatment with an investigational asthma drug. Approximately 100 participants are expected to take part in the USA.

To qualify for the VECTOR Study, you must:

  • be aged 12-21 years
  • have experienced moderate to severe asthma for at least one year
  • be eligible for the seasonal flu vaccine.

There are other criteria that you will need to meet to qualify, which the study team will discuss with you.

For further information about the VECTOR Study, contact our study team  by emailing or calling 210-851-8560

Apply Now:


Remdesevir Study

Ages Eligible for Study: Child, Adult, Older Adult
Sexes Eligible for Study: All


STAAMP Research will begin an outpatient treatment opportunity trial offering Remdesevir, a prodrug, to patients who have tested positive for the novel COVID-19 disease. This trial is free to the patients that participate and helps provide vital information to researchers as they continue to develop a treatment for current and emerging strains of the virus. An earlier study of the Remdesevir drug has shown that patients that receive the medication recovered up to four days faster than those patients who had not. Treatment intervention in the earlier phase of COVID-19 in an outpatient setting may prevent disease progression leading to hospitalization that would benefit patients and could reduce the burden on the healthcare system.